O ver the past 20 years, many studies have revealed increasing rates of psychotropic drug use among children, including psychostimulants and ADs. [1] [2] [3] [4] [5] These findings have sparked a debate concerning the appropriateness of treatment with psychotropic agents in this patient population, and have led to increased media attention and concern for the safety of children being prescribed these medications. [6] [7] [8] [9] [10] Much research to date has endeavoured to quantify the rising use of psychotropics among children, and to characterize epidemiologic patterns of drug use within this population, including differences according to sex, socioeconomic status, and ethnicity. 1, [11] [12] [13] [14] These studies have identified 2 trends of concern. First, an increasing number of children are being treated with multiple psychotropic agents. 2 Second, the trend of increased psychotropic use has been observed among children less than 6 years old, 15, 16 although others suggest that treatment in this age group is initiated only in conjunction with psychosocial services in children with predisposing risk factors. 17 More recent studies have demonstrated a continued rise in the use of psychotropics among children and adolescents both in the United States [3] [4] [5] 18, 19 and in Europe, 20, 21 and these trends are seen for psychostimulants 3, 4 and ADs. 5, 19, 20 However, there is much less data among Canadian children. Several studies have examined psychotropic drug use on a provincial level, including data from BC, 22 Ontario, 23 and MB, 24, 25 although most of the studies to date have focused exclusively on methylphenidate use. 3, 4, 22, 23 Despite this growing body of research concerning the use of psychotropics in children, few studies have examined geographical differences in drug use within this population. Further, studies of regional variation have generally limited their scope of analysis to one province or state, 14, 22, 24, 26 focused only on usage in urban or suburban settings, 27 or have confined their analysis to a narrow population based on insurance coverage. 28 Geographic comparisons are important in illustrating regional differences in disease prevalence, prescription drug policy, and physician practice patterns. Both the PharmaNet program in BC and the DPIN in MB collect considerable data concerning prescription drug use in these provinces, and this type of data lends itself to a comparison of drug use between these provinces. Thus the objective of our study was to determine if there are any differences in the patterns of stimulant and AD use among children less than 19 years of age in 2 Canadian provinces, MB and BC.
Method
This was a population-based comparison of the prescription use of psychostimulants and ADs among children living in MB and BC during 1997 to 2003.
Data were obtained on children from birth to 19 years of age from the Population Health Research Data Repository at the MB Centre for Health Policy and from the BC PharmaNet. These data are anonymized, encounter-based records of residents of MB and BC with the health care system. Two similar databases were used in each province: health care registration files and records of dispensed prescriptions in the DPIN in MB and in PharmaNet in BC.
The registration files contain a record for every individual eligible to receive insured health services, and include the individual's birthdate, sex, and geographic location. Prescription records are submitted to the DPIN and PharmaNet by retail pharmacies for reimbursement by the provincial drug insurance plans and for drug use review purposes. These records contain the drug's name, identification number, dosage form, and quantity dispensed, as well as the date of dispensation. Although these prescription data are used to describe drug use, we caution that each prescription record does not necessarily correlate with actual drug use. Nevertheless, by convention, we have employed the term use rather than prescription throughout the paper. Users were defined as the number of children with at least one prescription drug dispensed in the stated period. The reliability and validity of MB's DPIN database have been high for describing population drug use. For example, a study evaluating the quality of prescription data in DPIN found that database entries captured over 90% of prescriptions dispensed under the provincial plan. The accuracy of DPIN prescription drug data was 92%, compared with original prescription records. 29 The PharmaNet database is very similar to the DPIN database in structure and data capture, although we did not directly compare the properties of these 2 databases.
Psychostimulants were classified according to short-and long-acting methylphenidates, short-and long-acting amphetamines, and other. ADs were classified as SSRIs, SNRIs, TCAs, and other. Utilization rates were reported as number of prescriptions per 1000 children per annum from 1997 to 2003. The denominator was the population of 
Results
Between 1997 and 2003, psychostimulant use in children increased by 44.9% in MB, compared with an increase of only 13.3% in BC (see Figure 1 ). Higher rates of use were observed in males, compared with females, with a ratio of about 4:1 for both provinces. The rise in psychostimulant use among male children was 40.2% in MB and 8.6% in BC. Increases in use among female children were 69% in MB and 38% in BC.
Older children were more likely to receive a prescription for a psychostimulant in BC, as use was higher among the groups aged 11 to 14 and 15 to 18 years (with increases from 2.1% to 2.3% and 1.7% to 2.6%, respectively), compared with children aged 6 to 10 years (with increases from 1.9% to 1.6%, see Figure 2 ). In contrast, psychostimulant use in MB was highest among children aged 11 to 14 years (2.8% to 4%), followed by those aged 6 to 10 years (2.5% to 3.2%), while use in those aged 15 to 18 years was significantly lower (0.9% to 1.7%).
Type of psychostimulant prescribed also differed between the 2 provinces (see Table 1 ). Methylphenidate accounted for a greater proportion of all psychostimulants used in MB over the study period, as short-and long-acting preparations comprised 80.1% of psychostimulant prescriptions in MB, compared with 62.2% in BC. In 2003, 50% of psychostimulants were for short-acting methylphenidate in MB, in contrast to 29% in BC. However, both provinces saw increased use of D-amphetamine products from 1997 to 2003, and a decline in utilization of short-acting methylphenidate preparations (see Table 1 ).
Over this same period, we observed an increased use of ADs, a trend consistent in both provinces (75% in BC and 80% in MB, see Figure 3 ). However, after a steady incline in the use of ADs between 1997 and 1998 and 2001 and 2002, particularly among children aged 15 to 18 years, we observed a sharp decline in use during 2003 in both MB and BC.
There was also a marked increase in AD utilization among females and older children in both provinces. Whereas use of ADs was nearly equal between males and females in 1997, females accounted for the greater proportion of all AD prescriptions by 2003 (see Figure 3 ). AD utilization was also Year Users/1000 Population higher among older children in both provinces, with children aged 15 to 18 years being more likely to receive a prescription for an AD than children in the group aged 11 to 14 years (see Figure 4 ).
The pattern of use with respect to different classes of ADs was nearly identical for both provinces, with use of TCAs declining over the study period in favour of SNRIs and other newer agents, while use of SSRIs also increased (see Table 1 ). However, as a proportion of all ADs prescribed, SSRIs remained fairly stable, and continued to be the most widely prescribed agents throughout the study period (50% to 60% of all ADs).
Discussion
Our results indicate several key differences in the use of psychostimulants between children in MB and BC. First, psychostimulant prescription rates for both provinces were nearly identical in the late 1990s and increased over the next 6 years; however, the increase in use among MB children was more than 3-fold the rise found among BC children. Second, we observed differences in psychostimulant use according to age. In 2003, use in MB was highest among those aged 11 to 14 years, whereas use in BC children was higher in the group aged 15 to 18 years. This MB trend is consistent with a recent US study and an earlier study from MB, which found that psychostimulant use was highest among those aged 6 to 13 years. 4, 24 Finally, whereas psychostimulant use increased in all 3 age categories in MB, use in BC children aged 6 to 10 years actually decreased between 1997 and 2003.
One possible explanation for lower rates of psychostimulant use in BC involves more discriminate diagnosis and prescribing on the part of physicians in BC, either in response to literature concerns of increasing stimulant use in preschool children 15, 16 or to heightened surveillance of methylphenidate prescribing by the BC College of Physicians and Surgeons in 1998. Of interest, this BC licensing body reported that physicians were acting in accordance with general treatment guidelines for psychostimulants and were not engaging in indiscriminate prescribing. 30 The MB Physicians Prescribing Program was monitoring psychostimulant use in MB, but this program has not been in operation since the late 1990s.
Differing provincial drug insurance programs in MB and BC during the study period might also have a role in explaining the discrepant use of psychostimulants. Prior to 2003, BC residents were enrolled in a universal plan, and on reaching a fixed deductible, received 100% reimbursement for prescriptions, regardless of income. Under this policy, individuals with lower income paid a higher percentage of total earnings for the same medications than those in higher income brackets. 31 In May 2003, BC implemented a new drug benefits policy in which the deductible level was determined by family income. MB has had an income-based drug plan since 1996, in which individuals pay all prescription costs until they reach a deductible, determined by household income. Thereafter, the program covers 100% of prescription expenditures. Certainly, more equitable drug plans that reduce the financial burden of psychostimulant medication costs for low-income families should promote use within this population. Prior to the adoption of an income-based drug insurance plan, MB children from low-income families displayed the lowest rates of psychostimulant use, 24 and perhaps our observations of heightened use since this policy change are indicative of increased affordability of pharmaceuticals within this segment of the population. Further, we speculate that similar increases in psychostimulant use among BC children might be observed following the implementation of a comparable drug program in 2003. Prescription policy has been noted to determine psychostimulant use. For example, Canadian children living in families receiving health care subsidies are more likely to receive prescriptions for methylphenidate, 22 as are Medicaid-insured children in the United States, compared with those enrolled in a Health Maintenance Organization. 1, 12, 32 Notwithstanding these differences in stimulant use, there were several similarities in psychotropic use between provinces, primarily concerning ADs. Both provinces exhibited comparable increases (about 80%) in AD use over the study period. These values are somewhat higher than the 38% increase observed in the United States over the same period. 5 However, 1997 per capita rates of use in MB (0.68%) and BC (0.76%) were significantly lower than the 1.3% observed in the United States, and by 2002 our values more closely resembled those in the United States (1.8%). Moreover, our observations are similar to those from a UK study demonstrating a 70% increase in AD use among children between 1992 and 2001. 20 Additionally, trends in AD use according to age and sex were consistent among children from both provinces. We note a more pronounced increase in AD use among females, compared with males over the study period, consistent with observations from the recent US study. 5 Also, older children had higher rates of AD use in both provinces. This finding is supported by these earlier studies, illustrating a comparable trend, 5,20 although some regional variation has been documented. 19 We did observe a sharp decline in AD use in 2003 after steady increases from 1997 to 2002, which was consistent across age and sex. Apart from decreased use of TCAs observed throughout the study period, the greatest decline was observed for SSRIs in both provinces. This finding potentially reflects changes in drug use in response to cautions issued by both Health Canada and the US Food and Drug Administration in 2003 regarding the use of paroxetine in pediatric patients. 33 These well-publicized advisories were based on reports of increased suicidal ideation and suicide attempts among SSRI-treated children, in addition to studies suggesting SSRIs have little efficacy in this patient population. To our knowledge, to date, no Canadian studies have illustrated this change in AD use in reaction to the warnings issued by federal regulating bodies. Certainly, future studies examining AD use in children from 2000 to present are required to confirm our observations, especially since stronger warnings regarding the use of SSRIs in children were issued in 2004. 34, 35 Our 2-province comparison of psychotropic medication use in children possesses several key strengths. It is the first study to examine psychotropic drug use using administrative records from 2 large data repositories. This approach enabled us to investigate regional differences in drug use patterns using data that are nearly completely representative of the populations in question, and to thereby avoid any selection bias that would have otherwise limited our analysis. In using administrative claims data to measure drug use, we avoid the recall bias that potentially confounds self-reported measures of medication use.
Despite these strengths, we note several limitations of our study. Administrative claims data provide an excellent means of measuring drug use within a population, but they do not capture drug use from nonprescription sources, such as physician samples. Also, these data provide an indirect measure of drug use. We assume that each prescription recorded in the database represents prescriptions dispensed; however, we cannot directly measure patient adherence to medication regimens. Additionally, we are careful not to extrapolate our findings to a comparison of disease prevalence between provinces, because our study does not describe children diagnosed with a condition who do not receive pharmacologic treatment or those children who remain undiagnosed.
In summary, we observed significant regional variation in the use of psychotropic medications among Canadian children living in 2 provinces, which raises several important questions. Is there an increased prevalence of ADHD among MB children, compared with their BC counterparts? Are MB physicians more likely to endorse medication management over nonpharmacological measures such as behavioural therapy when treating ADHD? Do these different provincial rates of stimulant use represent inappropriate prescribing in MB children or, conversely, increased parental awareness of ADHD and, subsequently, increased care-seeking behaviour of these caregivers? Studies examining rates of diagnosis and service use, compared with drug use may elucidate whether our observations reflect differences in disease prevalence or merely opposing strategies to the management of complex psychiatric disorders. Also, further epidemiologic investigations examining differences regarding income level, ethnicity, urban and rural settings, and specialty of prescribing physicians will facilitate a better understanding of the regional variation we observed. 
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